The influence of amikacin on digoxin uptake by various rabbit tissues was investigated in vitro. 125J-digoxin was used and radioactivity was counted in a gamma scintillation counter. Amikacin decreases digoxin uptake by the renal tissue and this action is probably due to a displacing effect. On the contrary, amikacin increases digoxin uptake by striated and cardiac muscle. It is suggested that the latter action is due to a vasodilating effect of the aminoglycoside antibiotic that favors the microcirculation of the above tissues.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Green Tea Catechins as Perpetrators of Drug Pharmacokinetic Interactions.
Clin Pharmacol Ther
January 2025
Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Green tea (Camellia sinensis) is a commonly consumed beverage or dietary supplement. As a natural product with a myriad of proposed health benefits, patients are likely to consume green tea while taking their medications unaware of its potential to interact with drugs and influence drug efficacy and safety. Catechins are the abundant polyphenolic compounds in green tea (e.
View Article and Find Full Text PDFQuantitatively Predicting Effects of Exercise on Pharmacokinetics of Drugs Using a Physiologically Based Pharmacokinetic Model.
Drug Metab Dispos
October 2024
Department of Pharmacology, China Pharmaceutical University, Nanjing, China
Article Synopsis
- Exercise impacts various physiological functions, including increases in cardiac output and muscle blood flow, while decreasing glomerular filtration rate and liver blood flow, affecting how drugs are absorbed, distributed, metabolized, and excreted.
- The study developed a database of these changes during exercise and created equations to connect different physiological parameters with exercise intensity, using heart rate as a key index.
- The whole-body physiologically based pharmacokinetic (WB-PBPK) model demonstrated that drug concentrations during exercise could be predicted, showing significant effects of exercise conditions on drug pharmacokinetics based on sensitivity analysis.
Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma.
Eur Thyroid J
August 2024
Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands.
Objective: Patients with non-medullary thyroid carcinoma (NMTC) that are refractory to radioactive iodine (RAI) have a poor prognosis. Strategies for restoring the ability to take up iodine, so-called redifferentiation, are promising but not suitable for all patients. Preclinical studies, in human cell lines just as in a murine model, have shown that the cardiac glycoside digoxin restored RAI uptake.
View Article and Find Full Text PDFEvaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
CPT Pharmacometrics Syst Pharmacol
April 2024
Clinical Pharmacology, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Brigatinib is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive metastatic non-small cell lung cancer. In vitro studies indicated that brigatinib is primarily metabolized by CYP2C8 and CYP3A4 and inhibits P-gp, BCRP, OCT1, MATE1, and MATE2K. Clinical drug-drug interaction (DDI) studies with the strong CYP3A inhibitor itraconazole or the strong CYP3A inducer rifampin demonstrated that CYP3A-mediated metabolism was the primary contributor to overall brigatinib clearance in humans.
View Article and Find Full Text PDFTherapeutic Drug Monitoring (TDM) Implementation in Public Hospitals in Greece in 2003 and 2021: A Comparative Analysis of TDM Evolution over the Years.
Pharmaceutics
August 2023
Laboratory of Pharmacology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Therapeutic drug monitoring (TDM) is the clinical practice of measuring drug concentrations. TDM can be used to determine treatment efficacy and to prevent the occurrence or reduce the risk of drug-induced side effects, being, thus, a tool of personalized medicine. Drugs for which TDM is applied should have a narrow therapeutic range and exhibit both significant pharmacokinetic variability and a predefined target concentration range.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!